262 related articles for article (PubMed ID: 28558797)
1. Expression of signaling adaptor proteins predicts poor prognosis in pancreatic ductal adenocarcinoma.
Wang L; Lu J; Wu H; Wang L; Liang X; Liang Z; Liu T
Diagn Pathol; 2017 May; 12(1):42. PubMed ID: 28558797
[TBL] [Abstract][Full Text] [Related]
2. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
3. [Expression and clinical significance of Tspan 1 and Integrin α6 in human pancreatic ductal adenocarcinoma].
Shi G; Dong M; Sheng W; Zhou J; Yu D; Sun W
Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):781-6. PubMed ID: 25573220
[TBL] [Abstract][Full Text] [Related]
4. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
5. Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma.
Wang L; Wu H; Wang L; Lu J; Duan H; Liu X; Liang Z
Diagn Pathol; 2016 Jul; 11(1):60. PubMed ID: 27391842
[TBL] [Abstract][Full Text] [Related]
6. [The relationship and clinicopathological significance of Numb,MDM2 and p53 expression in human pancreatic cancer].
Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
Zhonghua Wai Ke Za Zhi; 2014 Sep; 52(9):675-81. PubMed ID: 25410780
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathological significance of ISYNA1 expression in pancreatic ductal adenocarcinoma].
Zhou L; Sheng WW; Shi XY; Zhou JP; Dong M
Zhonghua Wai Ke Za Zhi; 2019 Mar; 57(3):206-211. PubMed ID: 30861650
[No Abstract] [Full Text] [Related]
8. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
9. High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC).
Gong C; Zhang Y; Chen Y; Zhang H; Liu X; Xue H; Ji L; Wang L; Yang L; Zhou G; Wan C
Tumour Biol; 2015 Dec; 36(12):9189-99. PubMed ID: 26088450
[TBL] [Abstract][Full Text] [Related]
10. RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis.
Li X; Xiao Y; Fan S; Xiao M; Wang X; Chen X; Li C; Zong G; Zhou G; Wan C
Exp Mol Pathol; 2016 Oct; 101(2):176-186. PubMed ID: 27498047
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC).
Radulović P; Krušlin B
Bosn J Basic Med Sci; 2018 Aug; 18(3):246-251. PubMed ID: 29924959
[TBL] [Abstract][Full Text] [Related]
12. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.
Liu C; Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
Cancer Biomark; 2015; 15(6):735-43. PubMed ID: 26406402
[TBL] [Abstract][Full Text] [Related]
14. HBXIP protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Zhou X; Wang X; Duan J; Sun W; Chen Z; Li Q; Ou Z; Jiang G; Ren X; Liu S
Pathol Res Pract; 2019 Feb; 215(2):343-346. PubMed ID: 30583814
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of hepatocyte growth factor activator inhibitor type 1 (HAI-1) immunoreactivity in pancreatic ductal adenocarcinoma.
Sakugawa C; Haruyama Y; Tanaka H; Fukushima T; Kawaguchi M; Kataoka H
BMC Res Notes; 2017 Dec; 10(1):674. PubMed ID: 29202869
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay.
Liang X; Sun J; Wu H; Luo Y; Wang L; Lu J; Zhang Z; Guo J; Liang Z; Liu T
Diagn Pathol; 2018 Jan; 13(1):5. PubMed ID: 29378617
[TBL] [Abstract][Full Text] [Related]
17. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
[TBL] [Abstract][Full Text] [Related]
18. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
19. The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.
Yuan Y; Yang Z; Miao X; Li D; Liu Z; Zou Q
Tumour Biol; 2015 Dec; 36(12):9961-8. PubMed ID: 26178481
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
